Shares in Mylan (NSDQ:MYL) rose today after the EpiPen-maker met expectations on Wall Street with its 4th quarter results. The Canonsburg, Pa.-based company posted profits of $417.5 million, or $1.57 per share, on sales of $3.27 billion for the 3 months ended Dec. 31, for bottom-line growth of 114.5% on sales growth of 31.3% compared with the same […]
Respiratory
GlaxoSmithKline, Innoviva tout data for Relvar Ellipta inhaled drug combo
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) touted data today from a non-inferiority lung function study evaluating its inhaled, once-daily corticosteroid/long-acting beta2 agonist combination therapy in patients with asthma. The study showed that patients with well-controlled asthma could switch from the twice-daily Seretide Accuhaler to the companies’ once-daily Relvar Ellipta therapy without compromising lung function. Patients who switched to […]
Actelion reports income, revenue growth in FY2016
(Reuters) – Swiss drugmaker Actelion‘s 2016 core net income rose 27 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial hypertension (PAH), it said on Tuesday. Core net income rose to 881 million Swiss francs ($877.8 million) from 693 million francs in the previous year, the company said in a statement. […]
Acorda’s inhaled Parkinson’s drug meets primary endpoint in Phase III trial
Acorda Therapeutics (NSDQ:ACOR) said today that the phase III clinical trial evaluating its inhaled formulation of Parkinson’s drug levodopa met its primary endpoint. The drug was studied as a therapy for people with Parkinson’s disease experiencing “off” periods, or a re-emergence of symptoms. The randomized phase III trial enrolled 339 patients to evaluate the efficacy […]
Arms Pharmaceutical touts oral spray for upper respiratory tract infections
Arms Pharmaceutical touted data from a proof-of-concept clinical trial evaluating its oral spray formulation, Arms-I, for upper respiratory tract infections. The placebo-controlled trial demonstrated that the oral spray formulation is safe, well-tolerated and reduced influenza symptoms, according to the Cleveland-based pharmaceutical company. “The results confirm that our Arms-I technology has tremendous potential to lead the […]
Propeller Health, Novartis ink collaboration for connected inhaler
Propeller Health said today that it landed a collaborative agreement with Novartis (NYSE:NVS) to develop a custom add-on sensor for the Breezhaler inhaler. The partnership is focused on patients with chronic obstructive pulmonary disease in Europe. The Breezhaler is a capsule-based, dry powder inhaler and is a part of Novartis’ portfolio of COPD therapies. The custom […]
Pulmatrix raises $3m in direct offering
Pulmatrix (NSDQ:PULM) said today that unnamed institutional investors agreed to purchase approximately $3.3 million of shares of common stock in a direct offering. The company said it plans to sell 950,000 shares at $3.50 apiece. Pulmatrix expects the offering, which will close next week, to bring in $3.0 million in proceeds to use for general […]
Advanced Inhalation Therapies raises $10m
Advanced Inhalation Therapies closed a $10.2 million offering yesterday. According to regulatory filings, 39 investors contributed to the offering, which made its 1st sale on Jan. 13. The Israel-based company is developing a drug delivery device to treat severe respiratory infections and lung diseases using a high dose of nitric oxide. The company plans to use $604,000 […]
Cohero raises $13.3m for connected inhaler tech
Cohero Health said today that it raised more than $13.3 million, according to regulatory filings, in equity and Series A preferred stock. The company sold nearly all of its total offering amount of $13.6 million before closing the round. Over 50 investors have contributed to the offering, which had its 1st sale in October last year. […]
Mylan hit with antitrust lawsuit over EpiPen device
Mylan (NSDQ:MYL) said on Monday that it is undergoing an antitrust probe by the Federal Trade Commission into the company’s commercial practices regarding its EpiPen device. The Canonsburg, Pa.-based company reportedly responded to the allegations that it improperly fought off competition, saying “any suggestion that Mylan took any inappropriate or unlawful actions to prevent generic competition […]